Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications

Paolo Spagnolo, Giulio Rossi, Alberto Cavazza

Research output: Contribution to journalArticlepeer-review

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most common and lethal form of idiopathic interstitial pneumonia. The disease is thought to arise following an aberrant reparative response to recurrent alveolar epithelial cell injury leading to progressive loss of function. The median survival time is 3-5 years from diagnosis. Cigarette smoking, exposure to organic and inorganic dust and genetic factors have been shown to increase the risk of disease, although the cause of IPF remains elusive and its pathogenesis incompletely understood. In the last decade, several clinical trials evaluating novel therapies for IPF have been conducted but the results have been mostly disappointing. Conversely, compounds that target anti-fibrotic and growth factor pathways have been proven effective in slowing functional decline and disease progression. These promising results notwithstanding, truly effective therapeutic strategies will likely require combinations of drugs in order to target the multitude of pathways involved in disease pathogenesis.

Original languageEnglish
Pages (from-to)1005-1017
Number of pages13
JournalExpert Review of Clinical Immunology
Volume10
Issue number8
DOIs
Publication statusPublished - 2014

Keywords

  • Treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications'. Together they form a unique fingerprint.

Cite this